Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.07 USD | -1.84% | -6.49% | -19.16% |
Financials (USD)
Sales 2024 * | 50M | Sales 2025 * | 71.15M | Capitalization | 246M |
---|---|---|---|---|---|
Net income 2024 * | 5M | Net income 2025 * | 26M | EV / Sales 2024 * | 4.92 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.46 x |
P/E ratio 2024 * |
43.5
x | P/E ratio 2025 * |
9.74
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.71% |
Latest transcript on Fennec Pharmaceuticals Inc.
1 day | -1.84% | ||
1 week | -6.49% | ||
Current month | -18.44% | ||
1 month | -16.02% | ||
3 months | -10.02% | ||
6 months | +31.07% | ||
Current year | -19.16% |
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 11-08-24 |
Khalid Islam
CHM | Chairman | 67 | 14-04-24 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 9.07 | -1.84% | 182,107 |
24-04-23 | 9.24 | -1.49% | 288,706 |
24-04-22 | 9.38 | +0.43% | 165,455 |
24-04-19 | 9.34 | -2.40% | 143,207 |
24-04-18 | 9.57 | -1.34% | 159,693 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.16% | 246M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+0.99% | 22.2B | |
-16.53% | 21.23B | |
-8.61% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- FENC Stock